Compare

Aprea Therapeutics, Inc. vs Reviva Pharmaceuticals Holdings, Inc. vs Anixa Biosciences Inc vs Cerenome, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAprea Therapeutics, Inc.
APRE
Reviva Pharmaceuticals Holdings, Inc.
RVPH
Anixa Biosciences Inc
ANIX
Cerenome, Inc.
CNSY
Year ended2025-12-312025-12-312025-10-312025-12-31
Revenuen/an/an/a$5.21M
Revenue growth (YoY)n/an/an/a-10.5%
Gross marginn/an/an/an/a
Operating marginn/an/an/a-293.5%
Net marginn/an/an/a-429.4%
Net income-$12.60M-$19.86M-$10.93M-$22.39M
EPS (Diluted)-$1.93n/a-$0.34-$0.29
Operating cash flow-$12.89M-$24.59M-$7.17M-$20.77M
Free cash flown/an/an/a-$20.84M
Cash & equivalents$14.60M$14.44M$1.24M$4.26M
Total assets$15.93M$15.92M$16.08M$16.32M
Total liabilitiesn/a$7.28M$2.13M$12.33M
Shareholders' equity$12.44M$8.65M$15.16M$4.00M
Return on year-end equity-101.3%-229.7%-72.1%-560.2%
Shares outstanding8.19M5.87M33.01M138.68M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAprea Therapeutics, Inc.Reviva Pharmaceuticals Holdings, Inc.Anixa Biosciences IncCerenome, Inc.
Latestn/an/a$210.0K
Ended 2024-10-31
$5.21M
Ended 2025-12-31
1 year earliern/an/a$210.0K
Ended 2023-10-31
$5.82M
Ended 2024-12-31
2 years earliern/an/an/a$4.91M
Ended 2023-12-31
3 years earliern/an/a$512.0K
Ended 2021-10-31
n/a
4 years earliern/an/an/an/a